



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1450 Alexandria, Viginia 22313-1450 www.upite.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/629,074	07/31/2000	RONALD G CRYSTAL	205965	5286	
23460 7	590 06/17/2003				
LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE			EXAMINER		
			FALK, ANNE MARIE		
CHICAGO, IL 60601-6780			ART UNIT	PAPER NUMBER	
			1632	18	
			DATE MAILED: 06/17/2003	DATE MAILED: 06/17/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Applicant(s Application No. 09/629,074 CRYSTAL ET AL. **Advisory Action** Art Unit Examiner 1632 Anne-Marie Falk, Ph.D. --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 12 May 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. PERIOD FOR REPLY [check either a) or b)] a) The period for reply expires months from the mailing date of the final rejection. b) 🛛 The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1. A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: (a) they raise new issues that would require further consideration and/or search (see NOTE below); (b) they raise the issue of new matter (see Note below); (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. 3. Applicant's reply has overcome the following rejection(s): _____ 4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection. 7. ✓ For purposes of Appeal, the proposed amendment(s) a) ✓ will not be entered or b) ✓ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 22,23,25 and 27-33. Claim(s) objected to: Claim(s) rejected: 1-12,17-21,26 and 34-43. Claim(s) withdrawn from consideration: _____

U.S. Patent and Trademark Office

10. Other: ____

Inne-Marie Falle

Anne-Marie Falk, Ph.D. Primary Examiner

8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.

9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s).

/ C ntinuation Sheet (PTO-303) . 009/629,074





Application No.

Continuation of 2. NOTE: The proposed claim amendments would require new grounds of rejection under 35 U.S.C. 112, second paragraph. For example, Claims 2 and 3 depend from Claim 1 and recite "wherein at least one of the nucleic acids," thereby implying that more than one nucleic acid molecule may be present. However, since Claim 1 now recites "an adenoviral vector comprising at least one first nucleic acid encoding a vascular endothelial growth factor" and since the adenoviral vector comprises only one nucleic acid molecule (its genome) it is unclear what would constitute "the nucleic acids" referred to in Claims 2 and 3.

Continuation of 5. does NOT place the application in condition for allowance because: the claim amendments have not been entered. Claims 1-12, 17-21, 26, and 34-43 remain rejected for reasons of record.